Andra AP fonden Buys 1,800 Shares of Zoetis Inc. (NYSE:ZTS)

Andra AP fonden raised its stake in Zoetis Inc. (NYSE:ZTS) by 1.3% in the 4th quarter, HoldingsChannel reports. The firm owned 144,900 shares of the company’s stock after acquiring an additional 1,800 shares during the quarter. Andra AP fonden’s holdings in Zoetis were worth $23,609,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC increased its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Zoetis in the third quarter valued at $31,000. First Personal Financial Services bought a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the third quarter valued at $33,000. Finally, Dunhill Financial LLC increased its stake in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Zoetis Stock Up 0.2 %

Zoetis stock opened at $167.26 on Friday. The stock has a market cap of $74.90 billion, a PE ratio of 30.58, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The firm’s 50-day simple moving average is $166.61 and its 200 day simple moving average is $176.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.20%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is 36.56%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. StockNews.com cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Finally, Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.